Aspire Biopharma Files 8-K: Equity Sales & Accountant Change

Ticker: ASBPW · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1847345

Sentiment: neutral

Topics: unregistered-securities, accountant-change, corporate-actions

Related Tickers: ASBP

TL;DR

ASBP filed an 8-K on 9/22 reporting equity sales and accountant change. Check financials.

AI Summary

Aspire Biopharma Holdings, Inc. filed an 8-K on September 26, 2025, reporting on unregistered sales of equity securities and changes in its certifying accountant. The filing also includes financial statements and exhibits. The company was formerly known as PowerUp Acquisition Corp.

Why It Matters

This filing provides updates on the company's financial activities and auditor status, which are crucial for investors to assess the company's financial health and governance.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financial distress or dilution concerns for existing shareholders.

Key Players & Entities

FAQ

What specific type of equity securities were sold unregistered?

The filing indicates 'Unregistered Sales of Equity Securities' as an item, but does not specify the type or amount in the provided text.

Who is the new certifying accountant for Aspire Biopharma Holdings, Inc.?

The filing lists 'Changes in Registrant's Certifying Accountant' as an item, but the name of the new accountant is not provided in the excerpt.

When did Aspire Biopharma Holdings, Inc. change its name from PowerUp Acquisition Corp.?

The filing indicates a name change from PowerUp Acquisition Corp. on February 22, 2021.

What is the SIC code for Aspire Biopharma Holdings, Inc.?

The Standard Industrial Classification (SIC) code for Aspire Biopharma Holdings, Inc. is 2834, Pharmaceutical Preparations.

What is the state of incorporation for Aspire Biopharma Holdings, Inc.?

Aspire Biopharma Holdings, Inc. is incorporated in Delaware.

Filing Stats: 1,087 words · 4 min read · ~4 pages · Grade level 17.5 · Accepted 2025-09-26 17:10:30

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRE BIOPHARMA HOLDINGS, INC. Dated: September 26, 2024 By: /s/ Kraig Higginson Kraig Higginson Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing